Protelica's business model for commercializing the library is to work closely with industry partners to uncover new high affinity antibody
mimics directed towards targets of clinical and diagnostic significance," says Mike Honeysett, Protelica's Chief Business Officer.
Kymab, a monoclonal antibody biopharmaceutical company, announced today the launch of Kymouse HK, the first strain from the innovative Kymouse[TM] antibody discovery platform, which enables rapid discovery of high affinity antibody
These platforms harness the power of the in vivo immune system to yield very high affinity antibody
drug candidates with desirable characteristics of potency, specificity, solubility and reduced chances of immunogenicity.